Oncopeptides AB (publ) (ONCO.ST)
SEK 1.54
(1.18%)
SEK 1.54
(1.18%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 35.22 Million | 8.35 Million | 118.29 Million | - | - | - |
| Cost of Revenue | -1.07 Million | 6000.00 | 53.12 Million | 14.4 Million | 4.54 Million | 345 Thousand |
| Gross Profit | 36.29 Million | 8.34 Million | 65.17 Million | -14.4 Million | -4.54 Million | -345 Thousand |
| Operating Expenses | 289.74 Million | 357.69 Million | 1.48 Billion | 1.59 Billion | 739.39 Million | 419.3 Million |
| Selling, General and Administrative Expenses | 188.47 Million | 142.19 Million | 873.8 Million | 654.19 Million | 199.45 Million | 106.42 Million |
| Research and Development Expenses | 106.94 Million | 217.65 Million | 679.92 Million | 866.21 Million | 548.27 Million | 322.05 Million |
| Other Expenses | -5.68 Million | -2.15 Million | -67.64 Million | 70.87 Million | -8.33 Million | -9.17 Million |
| Cost and Expenses | 288.66 Million | 357.7 Million | 1.53 Billion | 1.59 Billion | 739.39 Million | 419.3 Million |
| Operating Income | -253.44 Million | -349.35 Million | -1.42 Billion | -1.59 Billion | -739.39 Million | -419.3 Million |
| Interest Expense | 5.78 Million | 883 Thousand | 948 Thousand | 1.48 Million | 528 Thousand | 2000.00 |
| Income Tax Expense | 664 Thousand | 271 Thousand | 8.94 Million | 2.25 Million | 785 Thousand | 147 Thousand |
| Earnings before Tax | -248.44 Million | -337.68 Million | -1.42 Billion | -1.59 Billion | -739.92 Million | -419.3 Million |
| Net Income | -249.11 Million | -337.95 Million | -1.43 Billion | -1.59 Billion | -740.7 Million | -419.44 Million |
| Earnings Per Share Basic | -1.96 | -4.11 | -19.00 | -25.57 | -14.33 | -9.77 |
| Earnings Per Share Diluted | -1.96 | -4.11 | -19.00 | -25.57 | -14.33 | -9.77 |
| Weighted Average Shares Outstanding | 126.83 Million | 82.32 Million | 75.29 Million | 62.36 Million | 51.7 Million | 42.92 Million |
| Weighted Average Shares Outstanding (Diluted) | 126.83 Million | 82.32 Million | 75.29 Million | 62.36 Million | 51.7 Million | 42.92 Million |
| Gross Margin | 1.03 | 1.00 | 0.55 | - | - | - |
| EBIT Margin | -6.58 | -38.26 | -11.88 | - | - | - |
| Profit Margin | -7.07 | -40.45 | -12.09 | - | - | - |
| EBITDA | -231.62 Million | -319.61 Million | -1.39 Billion | -1.57 Billion | -734.85 Million | -419.79 Million |
| Earnings Before Tax Margin | -7.20 | -41.81 | -12.01 | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 8.15 Million | 5.07 Million | 5.33 Million | 35.22 Million | 2.8 Million | 25.95 Million |
| Cost of Revenue | 947 Thousand | 287 Thousand | 781 Thousand | -1.07 Million | -1.89 Million | 25 Thousand |
| Gross Profit | 7.2 Million | 4.78 Million | 4.55 Million | 36.29 Million | 4.7 Million | 25.92 Million |
| Operating Expenses | 80.47 Million | 73.9 Million | 83.7 Million | 295.42 Million | 41.99 Million | 88.35 Million |
| Selling, General and Administrative Expenses | 52.61 Million | 45.66 Million | 50.63 Million | - | 40.98 Million | 51.59 Million |
| Research and Development Expenses | 27.86 Million | 28.24 Million | 33.07 Million | - | 6.27 Million | 37.53 Million |
| Other Expenses | -1.01 Million | - | - | 1.75 Million | - | - |
| Cost and Expenses | 81.42 Million | 74.19 Million | 84.48 Million | 294.34 Million | 40.1 Million | 88.38 Million |
| Operating Income | -73.26 Million | -69.12 Million | -79.14 Million | -259.12 Million | -37.29 Million | -62.43 Million |
| Interest Expense | - | 2.08 Million | - | 5.78 Million | 3.13 Million | - |
| Income Tax Expense | 22 Thousand | -47 Thousand | 2.08 Million | 664 Thousand | 112 Thousand | -284 Thousand |
| Earnings before Tax | -73.22 Million | -67.75 Million | -79.12 Million | -248.44 Million | -40.43 Million | -56.61 Million |
| Net Income | -73.24 Million | -67.7 Million | -81.21 Million | -249.11 Million | -40.54 Million | -56.33 Million |
| Earnings Per Share Basic | -0.35 | -0.53 | -0.90 | - | -0.45 | -0.62 |
| Earnings Per Share Diluted | -0.35 | -0.53 | -0.90 | - | -0.45 | -0.62 |
| Weighted Average Shares Outstanding | 211.26 Million | 126.9 Million | 90.23 Million | 126.83 Million | 90.43 Million | 90.36 Million |
| Weighted Average Shares Outstanding (Diluted) | 211.26 Million | 126.9 Million | 90.23 Million | 126.83 Million | 90.43 Million | 90.36 Million |
| Gross Margin | 0.88 | 0.94 | 0.85 | 1.03 | 1.68 | 1.00 |
| EBIT Margin | -8.98 | -12.95 | -13.15 | - | -13.30 | -2.41 |
| Profit Margin | -8.98 | -13.35 | -15.22 | -7.07 | -14.45 | -2.17 |
| EBITDA | -73.25 Million | -65.66 Million | -70.19 Million | - | -37.29 Million | -62.43 Million |
| Earnings Before Tax Margin | -8.98 | -13.63 | -14.83 | -7.36 | -13.30 | -2.41 |
PMREF
005420
SNTE
BCEKF
NTL
ALTOO